Reports of death with use of propofol (Diprivan) for nonprocedural (long-term) sedation and literature review.
Wysowski
Diane K
DK
Division of Drug Risk Evaluation, Office of Surveillance and Epidemiology, Food and Drug Administration, Silver Spring, Maryland 20993, USA. diane.wysowski@fda.hhs.gov
Pollock
Martin L
ML
D000138:Acidosis / Q000139:chemically induced; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D002319:Cardiovascular System / Q000187:drug effects; D002648:Child; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects*; D007022:Hypotension / Q000139:chemically induced; D007262:Infusions, Intravenous; D009026:Mortality; D015742:Propofol / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors; D012449:Safety; D013577:Syndrome; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D006993:Hypnotics and Sedatives; D015742:Propofol